ArticleCancer immunology, immunotherapy : CII2024

Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities.

Ryota Kikuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.